Alexion Pharmaceuticals (Nasdaq:ALXN) hit a new 52-week high Wednesday as it is currently trading at $117.69, above its previous 52-week high of $117.65 with 647,079 shares traded as of 3:40 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Alexion Pharmaceuticals (Nasdaq: ALXN) hit a new 52-week high Wednesday as it is currently trading at $117.69, above its previous 52-week high of $117.65 with 647,079 shares traded as of 3:40 p.m. ET. Average volume has been 1.2 million shares over the past 30 days. Alexion has a market cap of $22.39 billion and is part of the health care sector and drugs industry. Shares are up 63.1% year to date as of the close of trading on Tuesday. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 114.9, below the average drugs industry P/E ratio of 116 and above the S&P 500 P/E ratio of 17.7.
ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Alexion Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.